Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

Neil M. Iyengar; Joyce A. O’Shaughnessy; Heather N. Moore; Erika Hamilton; Komal L. Jhaveri; Cynthia X. Ma; Karen Tedesco; Monali Vasekar; Sarah Donahue; Hope S. Rugo

doi:10.1038/s41523-025-00864-2

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

Neil M. Iyengar
, Joyce A. O’Shaughnessy
, Heather N. Moore
, Erika Hamilton
, Komal L. Jhaveri
, Cynthia X. Ma
, Karen Tedesco
, Monali Vasekar
, Sarah Donahue
, Hope S. Rugo

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.

Original language	English (US)
Article number	16
Journal	npj Breast Cancer
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41523-025-00864-2
State	Published - Dec 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Access to Document

10.1038/s41523-025-00864-2

Cite this

Iyengar, N. M., O’Shaughnessy, J. A., Moore, H. N., Hamilton, E., Jhaveri, K. L., Ma, C. X., Tedesco, K., Vasekar, M., Donahue, S., & Rugo, H. S. (2026). Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. npj Breast Cancer, 12(1), Article 16. https://doi.org/10.1038/s41523-025-00864-2

@article{66a424de79844d71a48b3b9b3e7a3efd,

title = "Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion",

abstract = "Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor{\textendash}positive, human epidermal growth factor receptor 2{\textendash}negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.",

author = "Iyengar, \{Neil M.\} and O{\textquoteright}Shaughnessy, \{Joyce A.\} and Moore, \{Heather N.\} and Erika Hamilton and Jhaveri, \{Komal L.\} and Ma, \{Cynthia X.\} and Karen Tedesco and Monali Vasekar and Sarah Donahue and Rugo, \{Hope S.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = dec,

doi = "10.1038/s41523-025-00864-2",

language = "English (US)",

volume = "12",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer

T2 - expert opinion

AU - Iyengar, Neil M.

AU - O’Shaughnessy, Joyce A.

AU - Moore, Heather N.

AU - Hamilton, Erika

AU - Jhaveri, Komal L.

AU - Ma, Cynthia X.

AU - Tedesco, Karen

AU - Vasekar, Monali

AU - Donahue, Sarah

AU - Rugo, Hope S.

PY - 2026/12

Y1 - 2026/12

N2 - Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.

AB - Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.

UR - https://www.scopus.com/pages/publications/105028066591

UR - https://www.scopus.com/pages/publications/105028066591#tab=citedBy

U2 - 10.1038/s41523-025-00864-2

DO - 10.1038/s41523-025-00864-2

M3 - Review article

C2 - 41345397

AN - SCOPUS:105028066591

SN - 2374-4677

VL - 12

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 16

ER -

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this